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Vancomycin-associated acute kidney injury in critically-ill adolescent and young adult 
patients 
Abstract 
Background: Risk factors for the development of vancomycin-associated acute kidney injury 
have been evaluated in both pediatric and adult populations; however, no previous studies 
exist evaluating this in the critically-ill adolescent and young adult patients. Objective: Identify 
the incidence of acute kidney injury (AKI) and examine risk factors for the development of AKI 
in critically-ill adolescents and young adults on vancomycin.  Methods: This retrospective 
review evaluated the incidence of AKI in patients 15-25 years of age who received vancomycin, 
while admitted to an intensive care unit. AKI in this population was defined as an increase in 
serum creatinine by 0.5 mg/dL or 50% from baseline. Patients who developed AKI were 
evaluated for specific risk factors compared to those who did not develop AKI.  Results: A total 
of 50 patients (20 developed AKI) were included in the study. There was no difference in 
vancomycin daily dose or duration of vancomycin therapy.  Highest vancomycin trough 
(31.15mg/dL vs 12.5mg/dL, P=0.006), percentage of patients with concurrent nephrotoxic 
medication (95% vs 60%, P=0.012) and concurrent vasopressor (55% vs 23%, P=0.029) were 
higher in those who developed AKI. Percentage of patients who underwent a procedure while 
on vancomycin (35% vs 6.7%, P=0.021) was also higher within the AKI group. Conclusions: 
Vancomycin-associated AKI occurred in 40% of critically-ill adolescent and young adult patients. 
These patients may be more likely to develop vancomycin-associated AKI if they had undergone 
a procedure, as well as in the presence of high vancomycin trough levels, concurrent 




Vancomycin is a glycopeptide antibiotic that is commonly used for the empiric and 
targeted treatment of gram positive infections in critically ill patients.1–3 Achieving adequate 
treatment of these gram-positive infections, while avoiding adverse effects from vancomycin is 
a challenge that clinicians have been facing for many years. Vancomycin-associated acute 
kidney injury was initially attributed to impurities in the manufacturing of the product.4 It is 
now known that vancomycin directly produces renal tubular damage through oxidative stress, 
resulting in AKI.5,6 Factors such as concurrent use of other nephrotoxic agents, blood urea 
nitrogen (BUN) to serum creatinine ratio greater than 20:1 at initiation of therapy, vancomycin 
doses greater than 4 grams in 24 hours, and higher serum vancomycin trough levels have all 
been found to have an association with the development of AKI while receiving vancomycin.7,8 
It is also thought that more aggressive treatment goal troughs of greater than 15 mg/dL, 
supported by treatment guidelines, may contribute to the rate of vancomycin-associated AKI as 
well.1 The incidence of AKI has been reported as high as 43% in critically-ill patients being 
treated with vancomycin.9 
Studies have been conducted, in pediatric and adult populations, evaluating risk-factors 
of vancomycin-associated AKI.7,8,10–13 However, pediatric and adult populations differ in 
numerous ways and the development from childhood to adulthood differs among individuals.14 
Variations in all aspects of pharmacokinetics and pharmacodynamics are present between 
these two populations.15 There has yet to be any studies assessing risk factors of vancomycin- 
associated AKI, caused by vancomycin, specifically in the adolescent and young adult 
population.  Therefore, in this study, we aimed to determine the incidence of vancomycin-
 
 
associated AKI in critically ill adolescent and young adult-patients and evaluate the risk factors 
associated with development of this adverse event in patients on vancomycin therapy. 
Methods  
This study was a multi-center, retrospective chart review conducted at Indiana 
University (IU) Health’s downtown Academic Health Center (AHC) facilities located in 
Indianapolis, IN. This includes IU Health Methodist Hospital (625 bed adult hospital), IU Health 
University Hospital (339 bed adult hospital), and Riley Hospital for Children (255 bed pediatric 
hospital). At these institutions vancomycin is dosed by clinical pharmacists through a dosing 
consult protocol. This protocol does not lay out how vancomycin should be dosed or adjusted 
but allows the clinical pharmacist to dose and adjust the vancomycin based on their clinical 
judgement.  
After receiving approval by the Institutional Review Board, patients aged 15 - 25 years 
who received at least 48 hours of vancomycin while in the intensive care unit from July 1, 2014 
to June 30, 2016 were screened for inclusion to the study. Patients were included if they had a 
serum creatinine (Scr) value within the 48 hours prior to vancomycin initiation and at least one 
serum vancomycin trough level.  
Patients were excluded from analysis if they had a baseline Scr > 1.5 mg/dL, BMI of ≤ 15 
kg/m2 or ≥ 40 kg/m2, were an amputee, pregnant, had baseline kidney disease, a cystic fibrosis 
(CF) diagnosis, or were on extracorporeal membrane oxygenation (ECMO) or renal replacement 
therapy.  
Acute kidney injury in this population was defined as an increase in serum creatinine by 
0.5 mg/dL or 50% from baseline for two consecutive days. Upon identification of AKI incidence 
 
 
rate, patients were compared in two separate arms: 1) patients who developed AKI 2) patients 
who did not develop AKI. Data evaluated included: daily vancomycin dose, vancomycin trough 
levels, duration of vancomycin therapy, concurrent vasopressors, concurrent nephrotoxic 
medications (acyclovir, aminoglycosides, amphotericin B, calcineurin inhibitors, iodinated 
contrast agents, non-steroidal anti-inflammatory drugs [NSAID], piperacillin/tazobactam), 
procedures during therapy, and length of intensive care unit (ICU) stay. 
Presence of vancomycin-associated AKI was analyzed with an incidence rate. Descriptive 
statistics were utilized for subgroup analysis and identification of risk factors for the occurrence 
of AKI while on vancomycin. Categorical data were evaluated using Chi-squared and Fisher’s 
exact tests and continuous data were evaluated with the Wilcoxon Mann-Whitney U test. A p-
value <0.05 was considered as statistically significant. Analysis was performed in SPSS statistical 
software (IBM Corp., Armonk, N.Y., USA). 
Results 
A total of 418 vancomycin treatment courses were administered from July 1, 2014 to 
June 30, 2016 with 119 patients meeting initial inclusion. From these 119 patients, 69 patients 
were excluded due to a cystic fibrosis diagnosis, baseline kidney damage, BMI greater than 40, 
pregnancy, or ECMO cannulation; this resulted in a final study population of fifty patients. 
Twenty patients (40%) developed AKI. There were no differences in baseline demographics as 
seen in Table 1. 
There were no significant differences in vancomycin daily dose or duration of 
vancomycin therapy. However, median highest vancomycin trough level was 31.15 mcg/mL 
(11.28-46.68) in the AKI group compared to 12.5 mcg/mL (8.73-16.7) in the no AKI group 
 
 
(p=0.006). Percent of patients that underwent procedure during vancomycin therapy were 
significantly higher in the AKI group (35%) than the no AKI group (6.7%) (p=0.021). The 
procedures reported in these patients were orthopedic surgery (n=3), chest tube insertion 
(n=2), bone marrow aspiration (n=2), intestine transplant, and ventriculoperitoneal shunt 
placement(n=1). Table 2 summarizes the differences of factors between the two groups  
Patients who developed AKI had higher numbers of concurrent nephrotoxic medications 
than those who did not develop AKI (p=0.012). Figure 1 demonstrates that the presence of at 
least one concurrent nephrotoxic medication was also significantly higher in the AKI group with 
95% compared to 60% in the no AKI group (p=0.012). The most common concurrent 
nephrotoxic medication was piperacillin/tazobactam. Of patients who received at least one 
nephrotoxic medication, 65% received piperacillin/tazobactam in the no AKI group and 43.3% in 
the AKI group. Like the concurrent nephrotoxic medications, Figure 2 shows that concurrent 




To date, this is the first study that has evaluated the incidence of vancomycin-associated 
AKI in a focused population of critically ill adolescent and young adult patients. Here we report 
a 40% incidence of AKI in critically-ill adolescent and young adult patients. This is consistent 
with previously published studies evaluating vancomycin-associated AKI in critically-ill adult and 
pediatric patients that have reported a variable incidence from 5% to 43%.9 Factors such as high 
vancomycin doses, high vancomycin serum trough concentrations, and concurrent nephrotoxic 
medications have been identified as predictors of vancomycin-associated AKI in critically ill 
 
 
children. These factors, in addition to longer vancomycin days of therapy, obesity, and higher 
APACHE II scores, were associated with vancomycin-associated AKI in critically ill adults. In our 
study, we did not find a significant difference in vancomycin daily dose or duration of 
vancomycin therapy duration in patients that developed AKI compared to those that did not 
develop AKI. In fact, total daily dose of vancomycin was actually lower in patients who 
developed AKI. Patients that developed AKI did have a higher maximum vancomycin trough 
concentration in our study. Several studies have reported a significant association of high 
vancomycin serum trough concentrations with nephrotoxicity7,16,17.  Additionally, a report by 
Horey and colleagues identified a linear relationship between higher incidence of AKI and 
graded trough concentrations.18 Like the majority of previous evaluations of risk factors in 
vancomycin-associated AKI, this study identified a significant association with higher 
vancomycin trough concentrations and incidence of AKI. This factor is difficult to interpret 
however, as it is not clear whether the kidney injury is a result of the higher trough level or if 
the level is a result of the reduction in clearance due to the kidney injury.  Aside from routine, 
steady-state levels, random vancomycin trough levels are often checked when there is a change 
in the patient’s clinical status or with a suspected change in clearance/renal function. For the 
patients with a suspected decrease in renal function, the injury may have already occurred, 
resulting in the elevated level. 
 Similar to preceding studies reporting incidence of vancomycin AKI, patients in our study 
that developed AKI had higher numbers of concurrent nephrotoxic medications than those who 
did not develop AKI. In a study evaluating acute kidney injury during vancomycin therapy in 
critically ill children, Totapally et al reported an association between the administration of 
 
 
concurrent nephrotoxic medications and the incidence of acute kidney injury.8 In 2015, 
Knoderer and colleagues found that the risk of AKI was higher in pediatric patients with 
concurrent use of vancomycin with acyclovir, amphotericin B, or piperacillin-tazobactam.19 
Adult studies have identified vancomycin in addition to piperacillin-tazobactam or 
aminoglycosides has also resulted in increased rates of AKI.20,21  
We have shown that the presence of concurrent vasopressors was associated with 
increased AKI. Jeffres et al. also found this association in adult patients who were being treated 
with vancomycin for MRSA pneumonia.22 Vasopressors and acute kidney injury have been a 
topic of discussion for many years.23 Increasing severity of hypotension has been associated 
with increased incidence of acute kidney injury in critically-ill patients.24 Patients requiring more 
vasopressors likely indicate a higher severity of hypotension. Similar to concurrent nephrotoxic 
medications, there were a significantly higher number of patients on at least one concurrent 
vasopressor who developed AKI in the critically-ill adolescent and young adult population in this 
study.  
 In our study, we have shown that patients who underwent a procedure were more likely 
to experience AKI. Surgical procedures can cause large shifts in fluid status and an increase in 
insensible losses.25 This can result in pharmacokinetic changes with vancomycin. These patients 
may require earlier and more frequent vancomycin trough level follow-up to help prevent this 
further insult to the kidneys. 
 We recognize that this study had some limitations. First, due to the retrospective study 
design and missing data, it was not feasible to calculate a severity-of-illness score. While there 
were no differences in baseline characteristics between groups, the lack of this score makes it 
 
 
difficult to understand how similar the groups were as it relates to acute kidney injury and 
vancomycin compared to AKI from critical illness alone. Second, the small sample size and study 
design prevented us from detecting any true causative factors. Lastly, we did not evaluate any 
long-term morbidity or mortality data in this study, thus the permanent effects cannot be 
determined. A prospective study would be required to confirm these results. 
Conclusion 
 Vancomycin-associated AKI occurred in 40% of critically-ill adolescent and young adult 
patients. These patients may be more likely to develop vancomycin-associated AKI in the 
presence of high vancomycin trough levels, concurrent nephrotoxic agents, and concurrent 
vasopressor therapy. Patients undergoing a procedure may also be at an increased risk 
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Table 1: Summary of demographic data for patients included in final analysis 
Characteristic No AKI (n=30) AKI (n=20) 
Age
a
 20.5 (19-22.25) 18.5 (17-21) 
Gender 
     Male 19 (63.3%) 12 (60%) 
Weight
a
 57.8 (52.63-84.28) 73.75 (54.55-94.05) 
BMI
a
 21.9 (18.56-27.43) 27.2 (19.84-33.46) 
Baseline Scr
a
 0.58 (0.46-0.73) 0.63 (0.37-0.78) 
aMedian (IQR) 




Table 2: Differences in evaluated factors between study groups 
Characteristic No AKI (n=30) AKI (n=20) P value 














Duration of therapy (days)
 a
 5.5 (4-8) 6.5 (4-7) 0.540 









 0 (0-0.25) 1 (0-1) 0.029 
Concurrent nephrotoxic medications (n)
 a
 1 (0-2) 2 (1-3) 0.012 
Procedure 2 (6.7%) 7 (35%) 0.021 
Length of ICU stay (days)
 a
 7.5 (4-14.25) 9.5 (7-24) 0.081 
aMedian (IQR) 
bActual body weight 
 
 


